Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immunome Inc IMNM

Healthcare Biotechnology
Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its... see more

Recent & Breaking News (NDAQ:IMNM)

Immunome to Present at the Stifel 2023 Healthcare Conference

Business Wire November 10, 2023

Immunome Reports Third Quarter 2023 Financial Results

Business Wire November 9, 2023

Immunome Appoints Jean-Jacques Bienaimé to Board of Directors

Business Wire November 8, 2023

Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer

Business Wire October 19, 2023

Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies

Business Wire October 3, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, KLR, IMNM

PR Newswire September 12, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMNM, CPRI, AVID

PR Newswire August 17, 2023

Immunome Reports Second Quarter 2023 Financial Results

Business Wire August 9, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WMC, SGTX, AJX, IMNM

PR Newswire July 18, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KDNY, WMC, IMNM, AJX

PR Newswire July 10, 2023

IMPORTANT ALERT: Halper Sadeh LLC Investigates DICE, IMNM, AJX

PR Newswire July 3, 2023

Shareholder Alert: Ademi LLP investigates whether Immunome, Inc. has obtained a Fair Price in its Private Placement and its transaction with Morphimmune

PR Newswire June 30, 2023

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Immunome, Inc. Merger

Newsfile June 29, 2023

IMNM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Immunome, Inc. Is Fair to Shareholders

Business Wire June 29, 2023

Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies

Business Wire June 29, 2023

Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity

Business Wire May 23, 2023

Immunome Reports First Quarter 2023 Financial Results

Business Wire May 5, 2023

Immunome Reports Fourth Quarter and Full Year 2022 Financial Results

Business Wire March 16, 2023

Immunome to Present at 13th Annual World ADC London Conference

Business Wire March 9, 2023

Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board

Business Wire February 8, 2023